Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Istaroxime - Windtree Therapeutics

Next Previous
Drug Profile

Istaroxime - Windtree Therapeutics

Alternative Names: Debio 0614; ISTA; PST-2744; ST-2744

Latest Information Update: 19 May 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator sigma-tau SpA
  • Developer sigma-tau SpA; Windtree Therapeutics
  • Class Amines; Androstanes; Cardiovascular therapies; Cyclopentanes; Heart failure therapies; Imines; Ketosteroids; Oximes; Phenanthrenes; Small molecules
  • Mechanism of Action Sarcoplasmic reticulum calcium-transporting ATPase stimulants; Sodium-potassium-exchanging ATPase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Acute heart failure; Cardiogenic shock; Decompensated heart failure

Most Recent Events

  • 13 May 2026 Seismic Pharmaceuticals Operations plans the phase II/III trial for Cardiogenic Shock (Combination-therapy) in July 2026 (IV, Infusion) (NCT07583446)
  • 30 Mar 2026 Seismic Pharma plans NMPA registration for istaroxime by 2027.
  • 14 Nov 2025 Windtree Therapeutics has patent protection for Istaroxime for Acute heart failure in Canada and Mexico

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top